NASDAQ$ZVRA
Zevra Therapeutics Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Reported third quarter financial results and corporate updates.
KemPharm reported Q3 2021 revenue of $2.0 million and a net loss of $0.05 per basic share. Total cash and cash equivalents were $131.5 million as of September 30, 2021. The U.S. commercial launch of AZSTARYS® was initiated on July 21, 2021.
- Richard W. Pascoe appointed as Executive Chairman.
- Company uplisted to The Nasdaq Global Select Market.
- U.S. commercial launch of AZSTARYS initiated on July 21, 2021.
- AZSTARYS data presented at multiple medical conferences during ADHD Awareness Month.
Headline financials
Revenue & EPS history
Zevra · Revenue · Quarterly
$1.97M
Forward guidance
KemPharm is focused on expanding its pipeline and commercialization capabilities, with the advancement of the SDX program and data from the ongoing SDX clinical trial expected before year-end.
Tailwinds
- Continued commercialization of AZSTARYS.
- Further development of KemPharm’s pipeline of product candidates.
- Advancement of SDX program.
- Data from ongoing SDX clinical trial expected before year-end.
- Focus on pipeline development opportunities.
Headwinds
- Uncertainties and risks that could significantly affect current plans.
- Risks described in detail in KemPharm’s Quarterly Report on Form 10-Q.
- No obligation to update or alter forward-looking statements.
- Potential impact of market conditions on commercialization efforts.
- Dependence on Corium's commercialization of AZSTARYS.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
-0.2%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+3.8%
Avg return
30 days after
45%
20 / 44 earnings
Positive
+35.2%
Q2 2015
Best reaction
-19.4%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.0% | +1.6% | -0.1% | |
| Q4 2025 | +21.3% | +9.4% | +6.5% | |
| Q3 2025 | -9.8% | -6.4% | -13.5% | |
| Q1 2025 | +3.0% | +2.7% | +8.3% | |
| Q4 2024 | -2.1% | -2.1% | +10.5% | |
| Q3 2024 | -3.5% | -3.8% | -5.8% | |
| Q2 2024 | +2.6% | +8.2% | +11.5% | |
| Q1 2024 | -2.7% | -5.5% | -10.1% | |
| Q4 2023 | -13.3% | -13.9% | -23.9% | |
| Q3 2023 | -3.5% | -9.0% | +12.7% | |
| Q2 2023 | +3.8% | -4.2% | -2.7% | |
| Q1 2023 | +3.1% | +27.7% | +37.1% | |
| Q4 2022 | -19.4% | -22.8% | +4.9% | |
| Q3 2022 | -18.3% | -17.6% | -19.7% | |
| Q2 2022 | -5.4% | -14.6% | -4.3% | |
| Q1 2022 | +2.0% | +15.9% | +9.5% | |
| Q4 2021 | -4.7% | -1.3% | -15.3% | |
| Q3 2021 | -0.1% | -2.1% | -9.9% | |
| Q2 2021 | -9.4% | -7.2% | -7.6% | |
| Q1 2021 | +3.4% | +10.8% | +65.9% | |
| Q4 2020 | +19.5% | +14.4% | -8.3% | |
| Q3 2020 | -5.2% | +6.2% | +83.0% | |
| Q2 2020 | +8.7% | +46.8% | +48.9% | |
| Q1 2020 | -13.5% | -21.2% | -27.3% | |
| Q4 2019 | -0.9% | -8.5% | -30.9% | |
| Q3 2019 | +11.3% | -5.5% | -21.6% | |
| Q2 2019 | -15.8% | -18.3% | -25.8% | |
| Q1 2019 | +4.9% | +9.0% | +17.2% | |
| Q4 2018 | -14.6% | -16.2% | -32.4% | |
| Q3 2018 | -1.9% | -6.9% | +8.4% | |
| Q2 2018 | +5.5% | +0.0% | +13.7% | |
| Q1 2018 | +16.8% | +23.8% | +35.6% | |
| Q4 2017 | -9.9% | -13.2% | -29.1% | |
| Q3 2017 | +1.4% | +0.0% | +1.4% | |
| Q2 2017 | +8.5% | -8.5% | +9.3% | |
| Q1 2017 | +0.0% | +3.8% | +2.5% | |
| Q4 2016 | +9.7% | +18.1% | +31.9% | |
| Q3 2016 | +3.8% | +3.8% | -3.8% | |
| Q2 2016 | +0.0% | +7.7% | +22.0% | |
| Q1 2016 | -15.7% | — | — | |
| Q4 2015 | +0.7% | — | — | |
| Q3 2015 | -8.8% | — | — | |
| Q2 2015 | +35.2% | — | — | |
| Q1 2015 | -2.7% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro